ArticleJournal of neuro-oncology2025
Oncological value of MRI in brain metastasis: exploring the potential of combining post-contrast T1 TSE (SPACE) and T1 GRE (MPRAGE) for stereotactic radiosurgery planning and surveillance.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAccurate MRI-based detection of brain metastases (BM) is essential for planning stereotactic radiosurgery (SRS). Although spin-echo (SE) sequences such as T1-SPACE have shown superior lesion detectability compared with gradient-recalled echo (GRE)-based T1-MPRAGE, direct dosimetric comparisons and evaluations of clinical impact are lacking. This study aimed to quantitatively and qualitatively compare T1-SPACE and T1-MPRAGE sequences for SRS planning, focusing on lesion detectability, target volume delineation, dosimetric effects, and oncological outcomes.
methodsQuantitative, qualitative, and dosimetric analyses were performed in 51 patients who underwent MRI with T1-SPACE and T1-MPRAGE sequences prior to SRS (SPACE group). An experienced neuroradiologist identified BM on both sequences as the reference standard. For outcome evaluation, distant brain metastasis-free survival (DBMFS) and overall survival (OS) were compared between the SPACE group and a matched control group (n = 51) planned exclusively on the T1-MPRAGE sequence.
resultsA senior resident identified significantly more BM on T1-SPACE (94.7%) than on T1-MPRAGE (82.4%). T1-SPACE also demonstrated significantly higher contrast and contrast-to-noise ratios (p < 0.001). Dosimetrically, T1-SPACE-based plans showed smaller planning target volumes (p = 0.008) and modest but significant reductions in irradiated brain volumes (V12Gy and V10Gy, both p < 0.05). Patients planned with T1-SPACE had longer DBMFS (10.4 vs. 5.2 months, p = 0.024) and better OS (p = 0.049) compared with the control group.
conclusionThe T1-SPACE sequence offers superior lesion detectability, more accurate target delineation, and favorable dosimetric and clinical outcomes in patients with BM. These findings support the implementation of T1-SPACE as a standard imaging sequence for SRS planning in patients with BM. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.